A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults

Summary

This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.

Timeline

Start

2006-10

Primary completion

2007-08

Completion

2009-01

Drugs

Indications